Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind study of osilodrostat in Cushing's disease
2014-004092-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Corticotropin adenoma (ACTHoma) comparing Osilodrostat with Placebo (2 arms). Primary endpoint: Complete response at Week 12. Started Mar 2016; status: completed.
02
Drugs
osilodrostat
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2014-004092-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004092-23.